Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BYO
|
|||
| Former ID |
DCL001203
|
|||
| Drug Name |
ISIS-SOD1
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Amyotrophic lateral sclerosis [ICD-11: 8B60.0; ICD-9: 335.2] | Phase 1 | [1] | |
| Motor neurone disease [ICD-11: 8B60; ICD-10: G12.2; ICD-9: 335.2] | Phase 1 | [2] | ||
| Company |
ISIS Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SOD1 messenger RNA (SOD1 mRNA) | Target Info | . | [1] |
| BioCyc | Reactive oxygen species degradation | |||
| KEGG Pathway | Peroxisome | |||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Huntington's disease | ||||
| Prion diseases | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Degradation of Superoxides | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| Detoxification of Reactive Oxygen Species | ||||
| WikiPathways | Oxidative Stress | |||
| Copper homeostasis | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Nifedipine Activity | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Dopamine metabolism | ||||
| AGE/RAGE pathway | ||||
| Folate Metabolism | ||||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
| REF 2 | ClinicalTrials.gov (NCT01041222) Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.